New Strategies for Assessment of the Persistence of Viable Bacilli in Latent and Active Tuberculosis

Launched by REGION SKANE · Nov 10, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at new ways to identify if people with latent tuberculosis (TB) still have live bacteria in their bodies. Currently, some tests can’t tell the difference between those who have inactive TB (latent) and those who might still have living bacteria. This can lead to unnecessary treatment, which can be harmful. The main goal of this study is to find specific markers that indicate the presence of live bacteria, helping to reduce the use of unnecessary antibiotics.

If you're between the ages of 15 and 25 and have been diagnosed with latent TB, you may be eligible to participate in the study. Participants will need to provide informed consent and cannot have active TB, chronic illnesses, or be on immunosuppressive treatments. The study is currently recruiting participants and aims to gather information to improve the way we assess and treat latent TB, ultimately making the process safer for everyone involved.

Gender

ALL

Eligibility criteria

• • LTBI (2 groups)
• Inclusion Criteria:
• • latent tuberculosis: Interferon gamma (IFN-γ) \>0.70 IU/ml in the Quantiferon-TB Plus assay
• • age 15-25 years OR high likelihood of recent TB transmission
• • informed consent
• Exclusion Criteria:
• • active tuberculosis
• • chronic illness
• • immunosuppressive treatment
• • pregnancy (including 6 months post-partum)
• • previous treatment for either active or latent TB infection
• • Controls
• Inclusion Criteria:
• • age 15-25 years
• • informed consent
• Exclusion Criteria:
• • latent- OR active tuberculosis
• • chronic illness
• • immunosuppressive treatment
• • pregnancy (including 6 months post-partum)
• • previous treatment for either active or latent TB infection
• • Active TB
• Inclusion Criteria:
• • diagnosed with active TB
• • informed consent
• Exclusion Criteria:
• • age \< 15 years